Trial Profile
An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FREEDOM-EXT
- Sponsors United Therapeutics Corporation
- 14 Apr 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 This trial is completed in Italy, according to European Clinical Trials Database record.
- 08 Aug 2014 New trial record